Most material SEC filings — September 1, 2026

BioXcel Therapeutics filed an 8-K on 2026-09-01 disclosing Item 2.03 (creation of direct financial obligation) and Item 3.01 (delisting notice or listing standards failure). No specific dollar amounts, counterparties, dates, or terms are disclosed in the header metadata. The filing indicates potential exchange delisting and a new financial obligation, but concrete details are absent from available text.

XTI Aerospace (market cap $29.2M) received a Nasdaq deficiency notice on August 26, 2026 for failure to timely file its Q2 2026 Form 10-Q. The delay stems from an internal review of the former CEO who resigned August 17, 2026, and related corporate governance matters. Nasdaq granted until October 26, 2026 to submit a compliance plan, with potential 180-day extension to February 22, 2027; filing no Form 10-Q within that window risks suspension or delisting.

On August 31, 2026, 3i LP closed a $7.74M investment in Valion Bio: $100K in Series B Preferred Shares (100 shares) with warrants for 3,077 common shares at $3.62/share; and $7.637M in Series C Preferred Shares (7,637 shares) with warrants for 1,053,969 common shares at $3.62/share. Of this amount, $6.137M satisfied overdue cash true-up obligations, $100K covered legal fees, and $1.5M was paid to the company. Separately, Lisa Wolf was promoted from CFO to President and COO (retaining CFO duties) following Michael K. Handley's departure as CEO; board directors Jared Malbin and Thomas Jensen were appointed.

AEye announced September 1, 2026 that Lunar Outpost selected its Apollo lidar for integration onto the Pegasus Lunar Terrain Vehicle for NASA's Artemis lunar missions. The contract is described as "multi-million-dollar" but no specific dollar amount, payment schedule, or unit volume is disclosed. This marks AEye's entry into space mobility, expanding beyond automotive, defense, and industrial markets.

Following FDA End-of-Phase 2 meetings, Upstream Bio announced pivotal Phase 3 development plans for verekitug: two placebo-controlled trials (one per indication) enrolling ~1,500 patients total, dosing 400mg subcutaneously every 12 weeks, with initiation planned Q1 2027. Primary endpoints are annualized asthma exacerbation rates (48 weeks) for asthma and nasal polyp/congestion scores (48 weeks) for CRSwNP. Company expects potential BLA submission and launch as early as 2030 pending positive results.

Invivyd appointed Marc W. Elia, current Chairman since June 2022, as Chief Executive Officer effective August 30, 2026. Elia receives $750,000 annual base salary, 70% target bonus ($525,000), $500,000 sign-on bonus, and a grant of 10,700,000 stock options at fair market value with 4-year vesting (25% year 1, remaining 75% monthly over years 2–4). Employment is at-will but includes severance protections: 12 months base plus target bonus if terminated without cause; 18 months base plus target bonus if terminated without cause during a change-of-control period. Change-in-control bonus up to 1.5% of equity value (if deal ≥$20B) also included. Ajay Royan (Mithril Capital founder) became Lead Independent Director; Ian Sheffield joined the board.

Enovis entered into a binding offer to acquire eCential Robotics for approximately $176M in cash to shareholders at closing, plus up to $35M in contingent consideration based on milestone achievement. The deal expands Enovis's ASTRA enabling technology platform with robotic surgery capabilities and creates a robotics center of excellence in Grenoble, France. Expected to close by year-end 2026; company expects 100 basis points of adjusted EBITDA margin headwind in 2027 but returns to year-over-year improvement in 2028.